BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 27626495)

  • 21. De novo malignancy after lung transplantation in Japan.
    Miyazaki T; Oto T; Okumura M; Date H; Shiraishi T; Okada Y; Chida M; Kondo T; Nagayasu T
    Gen Thorac Cardiovasc Surg; 2016 Sep; 64(9):543-8. PubMed ID: 27270709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
    Aguiar D; Martínez-Urbistondo D; D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Sangro B; Quiroga J; Herrero JI
    Ann Transplant; 2017 Mar; 22():141-147. PubMed ID: 28302995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. De novo malignancy post-liver transplantation: a single center, population controlled study.
    Chatrath H; Berman K; Vuppalanchi R; Slaven J; Kwo P; Tector AJ; Chalasani N; Ghabril M
    Clin Transplant; 2013; 27(4):582-90. PubMed ID: 23808800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronologically different incidences of post-transplant malignancies in renal transplant recipients: single center experience.
    Ju MK; Joo DJ; Kim SJ; Huh KH; Kim MS; Jeon KO; Kim HJ; Kim SI; Kim YS
    Transpl Int; 2009 Jun; 22(6):644-53. PubMed ID: 19220824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation.
    Saigal S; Norris S; Muiesan P; Rela M; Heaton N; O'Grady J
    Liver Transpl; 2002 May; 8(5):482-7. PubMed ID: 12004349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gender, Race and Disease Etiology Predict De Novo Malignancy Risk After Liver Transplantation: Insights for Future Individualized Cancer Screening Guidance.
    Bhat M; Mara K; Dierkhising R; Watt KD
    Transplantation; 2019 Jan; 103(1):91-100. PubMed ID: 29377876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study.
    Yates WB; Vajdic CM; Na R; McCluskey PJ; Wakefield D
    Ophthalmology; 2015 Feb; 122(2):265-73. PubMed ID: 25312044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age.
    Tjon AS; Sint Nicolaas J; Kwekkeboom J; de Man RA; Kazemier G; Tilanus HW; Hansen BE; van der Laan LJ; Tha-In T; Metselaar HJ
    Liver Transpl; 2010 Jul; 16(7):837-46. PubMed ID: 20583092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation.
    Song JL; Gao W; Zhong Y; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG; Jiang L; Yang J
    World J Gastroenterol; 2016 Feb; 22(6):2133-41. PubMed ID: 26877618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology of post-transplant malignancy in Asian renal transplant recipients: a population-based study.
    Hsiao FY; Hsu WW
    Int Urol Nephrol; 2014 Apr; 46(4):833-8. PubMed ID: 24009082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. National survey of de novo malignancy after solid organ transplantation in Japan.
    Miyazaki T; Sato S; Kondo T; Kusaka M; Gotoh M; Saiki Y; Ono M; Kokudo N; Enosawa S; Satoh S; Soeda E; Furukawa H; Kobayashi E; Nagayasu T
    Surg Today; 2018 Jun; 48(6):618-624. PubMed ID: 29380136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival.
    Herrero JI; Lorenzo M; Quiroga J; Sangro B; Pardo F; Rotellar F; Alvarez-Cienfuegos J; Prieto J
    Liver Transpl; 2005 Jan; 11(1):89-97. PubMed ID: 15690541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. De novo malignancies after liver transplantation: a single-center experience.
    Hegab B; Khalaf H; Allam N; Azzam A; Al Khail FA; Al-hamoudi W; Kamel Y; Al Bahili H; Al Sofayan M; Al-Sebayel M
    Ann Saudi Med; 2012; 32(4):355-8. PubMed ID: 22705604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence, Risk Factors and Outcomes of Delayed-onset Cytomegalovirus Disease in a Large Retrospective Cohort of Lung Transplant Recipients.
    Santos CA; Brennan DC; Yusen RD; Olsen MA
    Transplantation; 2015 Aug; 99(8):1658-66. PubMed ID: 25675196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longterm Risk of Solid Organ De Novo Malignancies After Liver Transplantation: A French National Study on 11,226 Patients.
    Sérée O; Altieri M; Guillaume E; De Mil R; Lobbedez T; Robinson P; Segol P; Salamé E; Abergel A; Boillot O; Conti F; Chazouillères O; Debette-Gratien M; Debray D; Hery G; Dharancy S; Durand F; Duvoux C; Francoz C; Gugenheim J; Hardwigsen J; Houssel-Debry P; Jacquemin E; Kamar N; Latournerie M; Lebray P; Leroy V; Mazzola A; Neau-Cransac M; Pageaux GP; Radenne S; Saliba F; Samuel D; Vanlemmens C; Woehl-Jaegle ML; Launoy G; Dumortier J
    Liver Transpl; 2018 Oct; 24(10):1425-1436. PubMed ID: 30021061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of de novo malignancies after liver transplantation.
    Pillai AA
    Transplant Rev (Orlando); 2015 Jan; 29(1):38-41. PubMed ID: 25510578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review.
    Chak E; Saab S
    Liver Int; 2010 Oct; 30(9):1247-58. PubMed ID: 20602682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data.
    Jain AB; Yee LD; Nalesnik MA; Youk A; Marsh G; Reyes J; Zak M; Rakela J; Irish W; Fung JJ
    Transplantation; 1998 Nov; 66(9):1193-200. PubMed ID: 9825817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term probability of and mortality from de novo malignancy after liver transplantation.
    Watt KD; Pedersen RA; Kremers WK; Heimbach JK; Sanchez W; Gores GJ
    Gastroenterology; 2009 Dec; 137(6):2010-7. PubMed ID: 19766646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Betel quid chewing leads to the development of unique de novo malignancies in liver transplant recipients, a retrospective single center study in Taiwan.
    Chen YC; Cheng CH; Wang YC; Wu TJ; Chou HS; Chan KM; Lee WC; Lee CF; Soong RS
    Medicine (Baltimore); 2016 Sep; 95(37):e4901. PubMed ID: 27631265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.